Precision BioSciences (DTIL) Scheduled to Post Earnings on Monday

Precision BioSciences (NASDAQ:DTIL) will release its earnings data before the market opens on Monday, November 4th. Analysts expect Precision BioSciences to post earnings of ($0.79) per share for the quarter.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings results on Thursday, August 1st. The company reported $3.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $4.23. Precision BioSciences had a negative return on equity of 7.64% and a net margin of 19.36%. The company had revenue of $49.90 million during the quarter, compared to the consensus estimate of $8.50 million. During the same period in the previous year, the company posted ($3.00) earnings per share. On average, analysts expect Precision BioSciences to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Trading Up 5.4 %

Shares of NASDAQ:DTIL opened at $9.02 on Friday. Precision BioSciences has a 12-month low of $7.97 and a 12-month high of $19.43. The company has a market capitalization of $65.25 million, a PE ratio of 42.95 and a beta of 1.71. The business has a 50 day moving average of $9.39 and a two-hundred day moving average of $10.10.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a report on Thursday, August 22nd.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.